514 related articles for article (PubMed ID: 24618085)
1. Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor β1 signaling in metastatic breast cancers.
Wendt MK; Taylor MA; Schiemann BJ; Sossey-Alaoui K; Schiemann WP
Breast Cancer Res; 2014 Mar; 16(2):R24. PubMed ID: 24618085
[TBL] [Abstract][Full Text] [Related]
2. TGF-β stimulates Pyk2 expression as part of an epithelial-mesenchymal transition program required for metastatic outgrowth of breast cancer.
Wendt MK; Schiemann BJ; Parvani JG; Lee YH; Kang Y; Schiemann WP
Oncogene; 2013 Apr; 32(16):2005-15. PubMed ID: 22710711
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic targeting of neuropilin-1 prevents bypass signaling in drug-resistant breast cancer.
Abdullah A; Akhand SS; Paez JSP; Brown W; Pan L; Libring S; Badamy M; Dykuizen E; Solorio L; Andy Tao W; Wendt MK
Oncogene; 2021 Jan; 40(2):322-333. PubMed ID: 33128042
[TBL] [Abstract][Full Text] [Related]
4. Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer.
Brown WS; Tan L; Smith A; Gray NS; Wendt MK
Mol Cancer Ther; 2016 Sep; 15(9):2096-106. PubMed ID: 27371729
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer.
Wendt MK; Taylor MA; Schiemann BJ; Schiemann WP
Mol Biol Cell; 2011 Jul; 22(14):2423-35. PubMed ID: 21613543
[TBL] [Abstract][Full Text] [Related]
6. Modulation of NCAM/FGFR1 signaling suppresses EMT program in human proximal tubular epithelial cells.
Životić M; Tampe B; Müller G; Müller C; Lipkovski A; Xu X; Nyamsuren G; Zeisberg M; Marković-Lipkovski J
PLoS One; 2018; 13(11):e0206786. PubMed ID: 30383875
[TBL] [Abstract][Full Text] [Related]
7. FOXC1 Regulates FGFR1 Isoform Switching to Promote Invasion Following TGFβ-Induced EMT.
Hopkins A; Coatham ML; Berry FB
Mol Cancer Res; 2017 Oct; 15(10):1341-1353. PubMed ID: 28684636
[TBL] [Abstract][Full Text] [Related]
8. TGF-β1 promotes epithelial-to-mesenchymal transition and stemness of prostate cancer cells by inducing PCBP1 degradation and alternative splicing of CD44.
Chen Q; Gu M; Cai ZK; Zhao H; Sun SC; Liu C; Zhan M; Chen YB; Wang Z
Cell Mol Life Sci; 2021 Feb; 78(3):949-962. PubMed ID: 32440711
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting.
Cheng T; Roth B; Choi W; Black PC; Dinney C; McConkey DJ
PLoS One; 2013; 8(2):e57284. PubMed ID: 23468956
[TBL] [Abstract][Full Text] [Related]
10. BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression.
Kim SH; Ryu H; Ock CY; Suh KJ; Lee JY; Kim JW; Lee JO; Kim JW; Kim YJ; Lee KW; Bang SM; Kim JH; Lee JS; Ahn JB; Kim KJ; Rha SY
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30326563
[TBL] [Abstract][Full Text] [Related]
11. FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition.
Brown WS; Akhand SS; Wendt MK
Oncotarget; 2016 Dec; 7(50):83424-83436. PubMed ID: 27825137
[TBL] [Abstract][Full Text] [Related]
12. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
[TBL] [Abstract][Full Text] [Related]
13. Engagement of I-branching {beta}-1, 6-N-acetylglucosaminyltransferase 2 in breast cancer metastasis and TGF-{beta} signaling.
Zhang H; Meng F; Wu S; Kreike B; Sethi S; Chen W; Miller FR; Wu G
Cancer Res; 2011 Jul; 71(14):4846-56. PubMed ID: 21750175
[TBL] [Abstract][Full Text] [Related]
14. The FGFR1 inhibitor PD173074 induces mesenchymal-epithelial transition through the transcription factor AP-1.
Nguyen PT; Tsunematsu T; Yanagisawa S; Kudo Y; Miyauchi M; Kamata N; Takata T
Br J Cancer; 2013 Oct; 109(8):2248-58. PubMed ID: 24045665
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression.
Ji Q; Liu X; Han Z; Zhou L; Sui H; Yan L; Jiang H; Ren J; Cai J; Li Q
BMC Cancer; 2015 Mar; 15():97. PubMed ID: 25884904
[TBL] [Abstract][Full Text] [Related]
16. Targeted inactivation of β1 integrin induces β3 integrin switching, which drives breast cancer metastasis by TGF-β.
Parvani JG; Galliher-Beckley AJ; Schiemann BJ; Schiemann WP
Mol Biol Cell; 2013 Nov; 24(21):3449-59. PubMed ID: 24006485
[TBL] [Abstract][Full Text] [Related]
17. TNFAIP3 is required for FGFR1 activation-promoted proliferation and tumorigenesis of premalignant DCIS.COM human mammary epithelial cells.
Yang M; Yu X; Li X; Luo B; Yang W; Lin Y; Li D; Gan Z; Xu J; He T
Breast Cancer Res; 2018 Aug; 20(1):97. PubMed ID: 30111373
[TBL] [Abstract][Full Text] [Related]
18. Resistance to FGFR1-targeted therapy leads to autophagy via TAK1/AMPK activation in gastric cancer.
Peng R; Chen Y; Wei L; Li G; Feng D; Liu S; Jiang R; Zheng S; Chen Y
Gastric Cancer; 2020 Nov; 23(6):988-1002. PubMed ID: 32617693
[TBL] [Abstract][Full Text] [Related]
19. Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway.
Balanis N; Wendt MK; Schiemann BJ; Wang Z; Schiemann WP; Carlin CR
J Biol Chem; 2013 Jun; 288(25):17954-67. PubMed ID: 23653350
[TBL] [Abstract][Full Text] [Related]
20. FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy.
Quintanal-Villalonga Á; Ferrer I; Guruceaga E; Cirauqui C; Marrugal Á; Ojeda L; García S; Zugazagoitia J; Muñoz-Galván S; Lopez-Rios F; Montuenga L; Vicent S; Molina-Pinelo S; Carnero A; Paz-Ares L
EBioMedicine; 2020 Mar; 53():102683. PubMed ID: 32114392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
